CERVOMED INC. - COMMON STOCK

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

11 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed to Appoint William Elder as Chief Financial Officer

20 May 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

15 May 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

01 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed to Participate in Upcoming Investor Conferences

28 Mar 2024 16:05:00 By Nasdaq GlobeNewswire

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

28 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

05 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed to Participate in the BIO CEO and Investor Conference

21 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

12 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

07 Feb 2024 08:30:00 By Nasdaq GlobeNewswire

CervoMed to Participate in the Emerging Growth Conference 67

05 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed to Participate in the Emerging Growth Conference 66

05 Jan 2024 08:00:00 By Nasdaq GlobeNewswire